Optimizing Treatment for Human Immunodeficiency Virus to Improve Clinical Outcomes Using Precision Medicine
American Journal of Epidemiology · 2023
DOI: 10.1093/aje/kwad057 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Epidemiology, 2023. Verfasst von Michael Jetsupphasuk und 19 weiteren Autor:innen. Hauptthemen laut MEDLINE: HIV Infections, Acquired Immunodeficiency Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NEI NIH HHS, Intramural NIH HHS.
Abstract (Originalsprache)
In first-line antiretroviral therapy (ART) for human immunodeficiency virus (HIV) treatment, some subgroups of patients may respond better to an efavirenz-based regimen than an integrase strand transfer inhibitor (InSTI)-based regimen, or vice versa, due to patient characteristics modifying treatment effects. Using data based on nearly 16,000 patients from the North American AIDS Cohort Collaboration on Research and Design from 2009–2016, statistical methods for precision medicine were employed to estimate an optimal treatment rule that minimizes the 5-year risk of the composite outcome of acquired immune deficiency syndrome (AIDS)-defining illnesses, serious non-AIDS events, and all-cause mortality. The treatment rules considered were functions that recommend either an efavirenz- or InSTI-based regimen conditional on baseline patient characteristics such as demographic information, laboratory results, and health history. The estimated 5-year risk under the estimated optimal treatment rule was 10.0% (95% confidence interval (CI): 8.6, 11.3), corresponding to an absolute risk reduction of 2.3% (95% CI: 0.9, 3.8) when compared with recommending an efavirenz-based regimen for all patients and 2.6% (95% CI: 1.0, 4.2) when compared with recommending an InSTI-based regimen for all. Tailoring ART to individual patient characteristics may reduce 5-year risk of the composite outcome compared with assigning all patients the same drug regimen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Förderung
- NIDA NIH HHS
- NEI NIH HHS
- Intramural NIH HHS
- NIMHD NIH HHS
- NIAID NIH HHS
- NCRR NIH HHS
- NHLBI NIH HHS
- NIAAA NIH HHS
Zitieren
APA
Jetsupphasuk, M., Hudgens, M. G., Lu, H., Cole, S. R., Edwards, J. K., Adimora, A. A., Althoff, K. N., Silverberg, M. J., Rebeiro, P. F., Lima, V. D., Marconi, V. C., Sterling, T. R., Horberg, M. A., Gill, M. J., Kitahata, M. M., Moore, R. D., Lang, R., Gebo, K., Rabkin, C., & Eron, J. J. (2023). Optimizing Treatment for Human Immunodeficiency Virus to Improve Clinical Outcomes Using Precision Medicine. American Journal of Epidemiology. https://doi.org/10.1093/aje/kwad057
Vancouver
Jetsupphasuk M, Hudgens MG, Lu H, Cole SR, Edwards JK, Adimora AA, et al. Optimizing Treatment for Human Immunodeficiency Virus to Improve Clinical Outcomes Using Precision Medicine. American Journal of Epidemiology. 2023. doi:10.1093/aje/kwad057
BibTeX
@article{Jetsupphasuk2023,
author = {Jetsupphasuk, Michael and Hudgens, Michael G and Lu, Haidong and Cole, Stephen R and Edwards, Jessie K and Adimora, Adaora A and Althoff, Keri N and Silverberg, Michael J and Rebeiro, Peter F and Lima, Viviane D and Marconi, Vincent C and Sterling, Timothy R and Horberg, Michael A and Gill, M John and Kitahata, Mari M and Moore, Richard D and Lang, Raynell and Gebo, Kelly and Rabkin, Charles and Eron, Joseph J},
title = {Optimizing Treatment for Human Immunodeficiency Virus to Improve Clinical Outcomes Using Precision Medicine},
journal = {American Journal of Epidemiology},
year = {2023},
doi = {10.1093/aje/kwad057}
}
EUVIMED